Basit öğe kaydını göster

MALIGNANT MELANOMA AND SURVIVIN

dc.contributor.authorYasasever, Vildan
dc.contributor.authorOguz, Hilal
dc.contributor.authorTAŞ, Faruk
dc.contributor.authorTopuz, Erkan
dc.contributor.authorDURANYILDIZ, Hadiye Derya
dc.contributor.authorCamlica, Hakan
dc.date.accessioned2021-03-06T12:45:19Z
dc.date.available2021-03-06T12:45:19Z
dc.date.issued2005
dc.identifier.citationOguz H., DURANYILDIZ H. D. , Camlica H., TAŞ F., Yasasever V., Topuz E., "MALIGNANT MELANOMA AND SURVIVIN", TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, cilt.20, ss.27-29, 2005
dc.identifier.othervv_1032021
dc.identifier.otherav_f5582248-4549-4a13-93a2-ac2616e2bcfd
dc.identifier.urihttp://hdl.handle.net/20.500.12627/160814
dc.description.abstractAbnormalities in the control of apoptosis play an important role in tumorigenesis. We investigated the serum levels of an anti-apoptotic protein, survivin, in 44 patients with malignant melanoma using enzyme-linked immunosorbent assay (ELISA). There was no significant difference in the serum survivin level between melanoma patients and controls. In node positive patients the serum levels of survivin were unchanged after Interferon-alpha therapy but serum survivin concentrations were significantly higher in the metastatic patients than the controls.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleMALIGNANT MELANOMA AND SURVIVIN
dc.typeMakale
dc.relation.journalTURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
dc.contributor.departmentPrevantif Onkol Bilim Dali , ,
dc.identifier.volume20
dc.identifier.issue1
dc.identifier.startpage27
dc.identifier.endpage29
dc.contributor.firstauthorID2359149


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster